- Home
- RBBN vs ANAB Comparison
RBBN vs ANAB Comparison
Compare RBBN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBBN
- ANAB
- Stock Information
- Founded
- RBBN 1997
- ANAB 2005
- Country
- RBBN United States
- ANAB United States
- Employees
- RBBN N/A
- ANAB N/A
- Industry
- RBBN EDP Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- RBBN Technology
- ANAB Health Care
- Exchange
- RBBN Nasdaq
- ANAB Nasdaq
- Market Cap
- RBBN 671.1M
- ANAB 621.1M
- IPO Year
- RBBN 2000
- ANAB 2017
- Fundamental
- Price
- RBBN $3.97
- ANAB $20.22
- Analyst Decision
- RBBN Strong Buy
- ANAB Buy
- Analyst Count
- RBBN 4
- ANAB 10
- Target Price
- RBBN $6.00
- ANAB $48.00
- AVG Volume (30 Days)
- RBBN 504.8K
- ANAB 459.5K
- Earning Date
- RBBN 07-23-2025
- ANAB 08-06-2025
- Dividend Yield
- RBBN N/A
- ANAB N/A
- EPS Growth
- RBBN N/A
- ANAB N/A
- EPS
- RBBN N/A
- ANAB N/A
- Revenue
- RBBN $863,459,000.00
- ANAB $123,164,000.00
- Revenue This Year
- RBBN $7.26
- ANAB N/A
- Revenue Next Year
- RBBN $5.52
- ANAB $24.39
- P/E Ratio
- RBBN N/A
- ANAB N/A
- Revenue Growth
- RBBN 7.68
- ANAB 304.17
- 52 Week Low
- RBBN $2.84
- ANAB $12.21
- 52 Week High
- RBBN $5.38
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- RBBN 54.43
- ANAB 34.66
- Support Level
- RBBN $3.63
- ANAB $19.48
- Resistance Level
- RBBN $3.85
- ANAB $20.35
- Average True Range (ATR)
- RBBN 0.15
- ANAB 1.27
- MACD
- RBBN 0.00
- ANAB -0.13
- Stochastic Oscillator
- RBBN 74.07
- ANAB 18.49
About RBBN Ribbon Communications Inc.
Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).